In the wake of the heritable human genome editing (HHGE) experiments carried out by He Jiankui in China, 1 widely condemned as unethical and scientifically ill grounded, attention has shifted to questions concerning hard law and regulation. The World Health Organization (WHO) recently released a report along with several auxiliary documents exploring international governance tools for human genome engineering. 2 However, as long as such governance occurs only at the national legal level, the possibility of medical tourism to circumvent domestic prohibitions remains a risk.The risk is not merely theoretical. As with the case of mitochondrial replacement techniques, patients have left their home country for seemingly more permissive regimes in Greece, Spain, Mexico, and Ukraine to access such therapy. 3 The 2019 announcement of possibly establishing a germline-editing clinic in Russia is a case in point. 4 One solution would be an approach like an international treaty on genome editing. But the most recent report from the WHO did not pursue that avenue.Instead, the WHO largely relied on national implementation of governance tools to provide a translational pathway for potential HHGE uses as well as a way to publicly disclose and report on uses that deviate from